Neurocrine to acquire Prader-Will drug in $2.9B Soleno buyout

The deal hands Neurocrine a “controversial” medicine, Vykat, that achieved $190 million in sales last year but faces persistent questions about its growth trajectory and safety, according to Wall Street analysts.